+

WO1988000190A1 - Optically active derivatives of glycidol - Google Patents

Optically active derivatives of glycidol Download PDF

Info

Publication number
WO1988000190A1
WO1988000190A1 PCT/US1987/001523 US8701523W WO8800190A1 WO 1988000190 A1 WO1988000190 A1 WO 1988000190A1 US 8701523 W US8701523 W US 8701523W WO 8800190 A1 WO8800190 A1 WO 8800190A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
purified
produced
formula
glycidyl
Prior art date
Application number
PCT/US1987/001523
Other languages
French (fr)
Inventor
Karl Barry Sharpless
Tetsuo H. Onami
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/913,936 external-priority patent/US4946974A/en
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Publication of WO1988000190A1 publication Critical patent/WO1988000190A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals

Definitions

  • Optically active compounds have increasingly gained importance as the ability to manipulate the synthesis of other optically active compounds has improved.
  • a compound is optically active if its atoms are not superimposable upon those of its mirror image.
  • Isomers that are mirror images of each other are called enantiomers.
  • Enantiomers have the same physical properties except for this difference in geometrical shape, i.e. mirror image. This difference however, has Important consequences.
  • Obtaining asymmetric molecules has traditionally involved physically or chemically resolving the desired molecule from a racemic mixture of the two different optical forms.
  • a second method the chiral pool method, involves using naturally occurring asymmetric molecules as building blocks for the desired asymmetric molecule.
  • a third method has been developed which involves controlling the steps of the reaction so that only the desired enantiomer is produced (See U.S. Patent No. 4,471,130).
  • the titanium-catalyzed asymmetric epoxidation of allylic alcohols has been important in further refining the above-described controlled step process.
  • Homochiral glycidol has been useful in the synthesis of ⁇ -adrenergic blocking agents ( ⁇ -blockers).
  • glycidol is difficult to store and isolate because it is unstable.
  • the in situ derivation of glycidol where the unstable glycidol is derivatized after completion of the asymmetric epoxidation reaction rather than isolated directly from the reaction mixture has many benefits.
  • the derivatives are easier to handle, and they are more advanced synthetic intermediates than the parent glycidol.
  • the ability to obtain high enantiomeric purity for these glycidol derivatives can vary greatly. With many glycidol derivatives it has proven extremely difficult to improve the enantiomeric purity by crystallization.
  • the (2S)-glycidyl m-nitrobenzenesulfonate preferably is purified to at least about 94% e.e., preferably at least about 96% e.e., and even more preferably at least about 98% e.e. Yields up to 98.8% e.e have been obtained in accord with this invention.
  • the purity of the (2S)-glycidyl p-chlorobenzenesulfonate is preferably at least about 94% e.e. and more preferably at least about 95% e.e.
  • This compound is preferably purified to at least about 90% e.e. and even more preferably to at least about 94% e.e.
  • (2R)-glycidyl m-nitrobenzenesulfonate, (2R)-glycidyl ⁇ -chlorobenzenesulfonate and (2R)-glycidyl 4-chloro-3- nitrobenzenesulfonate can be similarly produced by using (+) -DIPT instead of (-)-DIPT.
  • (2R) compounds can be purified to the same enantiomeric purity as (2S) compounds.
  • the crystallized compound is stable and can easily be stored at room temperature until its use is desired.
  • the stability of these compounds means that they can be used commercially as "starting materials" in the synthesis of, for example, ⁇ -blockers.
  • starting materials for example, ⁇ -blockers.
  • a convenient, one-pot procedure can be employed to convert the glycidyl m-nitrobenzenesulfonate into an important intermediate to the ⁇ -blocker, propranolol, which can be converted to propranolol by the addition of i PrNH 2 and H 2 O in the reaction mixture.
  • X is m-nitro, p-chloro or 4-chloro-3- nltrobenzenesulfonate substituent
  • ArOH is an aromatic alcohol. Any aromatic alcohol capable of displacing the sulfonate moiety can be used in the reaction to create the desired intermediate. Preferable aromatic alcohols are those that yield desired ⁇ -blockers upon subsequent reaction with a predetermined amine. The appropriate amine to use can be readily determined by the person of ordinary skill in the art.
  • Crushed 3 ⁇ molecular sieves (Aldrich Chemical Co.) were activated by heating in a vacuum oven at 160oC and 0.05 mm Hg for at least 8 hours.
  • Diisopropyl tartrate and titanium (IV) isopropoxide (Aldrich) were distilled under vacuum and were stored under an inert atmosphere. Allyl alcohol and cumene hydroperoxide (tech., 80%, Aldrich) were dried prior to use over 3 ⁇ molecular sieves, but otherwise used as received.
  • Dichloromethane (EM Reagent) was not distilled, but was also dried over 3 ⁇ molecular sieves.
  • 1-Naphthol (Aldrich) was sublimed prior to use.
  • reaction mixture (stock solution A) (43 ml) was transferred into a 100-ml round-bottomed flask using a syringe, and triethylamine (4.2 ml, 2.05 g, 30 mmol) was added at -20°C, followed by addition of m-nitrobenzenesulfonyl chloride (4.43 g., 20 mmol) as a solution in 8 ml dichloromethane. The flask was stoppered and transferred to a freezer at -20oC.
  • the reaction mixture was diluted with water (5 ml) and extracted with ether (3 x 10 ml). The combined extracts were washed with sat. brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give crude crystalline glycidyl 1-naphthyl ether (98.8% e.e.). The e.e. was determined by NMR analysis (DCI 3 ) of the Mosher ester, which was prepared from the crude glycidyl 1-naphthyl ether according to the method described in Example 1.
  • (2S) -Glycidyl 4-chloro-3-nitrobenzenesulfonate was prepared using 4-chloro-3-nitrobenzenesulfonyl chloride instead of p-toluenesulfonyl chloride, according to the method described in Example 1.
  • Crude crystals mp 49-54°C, 41% yield which were obtained by the crystallization of an oil from diethyl etherpet, ether mixture, were recrystallized from ethanol-ethyl acetate mixture to give pure crystals, mp 54.7-55.2°C, 94% e.e.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)

Abstract

These compounds, (2S) and (2R) glycidyl m-nitrobenzenesulfonate, (2S) and (2R) glycidyl p-chlorobenzenesulfonate and (2S) and (2R) glycidyl 4-chloro-3-nitrobenzenesulfonate can be readily crystallized to high enantiomeric purity. Their use in other synthesis reactions is also described.

Description

OPTICALLY ACTIVE DERIVATIVES OF GLYCIDOL
Optically active compounds have increasingly gained importance as the ability to manipulate the synthesis of other optically active compounds has improved. A compound is optically active if its atoms are not superimposable upon those of its mirror image. Isomers that are mirror images of each other are called enantiomers. Enantiomers have the same physical properties except for this difference in geometrical shape, i.e. mirror image. This difference however, has Important consequences.
In living systems only one form of the stereoisomer generally functions properly. The other form typically either has no biological function or results in harm. In nature, the desired enantiomer is naturally synthesized. Synthetic chemists, in contrast, have rarely been as successful in making a pure enantiomer. They generally obtain racemic mixtures containing equal amounts of both optical forms of the molecule, i.e. dextrarotary (right-handed) and levorotary (left-handed). Consequently, these racemic mixtures do not exhibit properties based upon optical activity.
Obtaining asymmetric molecules has traditionally involved physically or chemically resolving the desired molecule from a racemic mixture of the two different optical forms. A second method, the chiral pool method, involves using naturally occurring asymmetric molecules as building blocks for the desired asymmetric molecule. A third method has been developed which involves controlling the steps of the reaction so that only the desired enantiomer is produced (See U.S. Patent No. 4,471,130).
While the latter method has resulted in a tremendous advance in the field, problems still remain. The control over the reaction process is often not complete, and both forms of the molecule can still be produced. Even a small amount of the undesired form of the enantiomer results in significant loss of optical purity in the resultant mixture because an equal amount of the desired form of the enantiomer is associated with the undesired form. Thus, a step which produces 90% of the desired enantiomer only results in 80% enantiomeric excess (% e.e.).
The titanium-catalyzed asymmetric epoxidation of allylic alcohols has been important in further refining the above-described controlled step process. Homochiral glycidol has been useful in the synthesis of β-adrenergic blocking agents (β-blockers).
However, glycidol is difficult to store and isolate because it is unstable. The in situ derivation of glycidol where the unstable glycidol is derivatized after completion of the asymmetric epoxidation reaction rather than isolated directly from the reaction mixture has many benefits. The derivatives are easier to handle, and they are more advanced synthetic intermediates than the parent glycidol. However, the ability to obtain high enantiomeric purity for these glycidol derivatives can vary greatly. With many glycidol derivatives it has proven extremely difficult to improve the enantiomeric purity by crystallization.
In substitution reactions of glycidol derivatives poor regioselectivity results in a substantial deterioration in the optical purity of the starting material. Consequently, it is desirable to find derivatives which approach optical purity, and which exhibit high regioselectivity in substitution reactions.
We have now discovered three compounds that are stable and can reach high enantiomeric purity. These compounds are (2S)-glycidyl m-nitrobenzenesulfonate, (2S)-glycidyl p-chlorobenzenesulfonate and glycidyl 4-chloro-3- nitrobenzenesulfonate. These compounds can readily be produced from allylic alcohol and crystallized to extremely high enantiomeric purity. With recrystallization it is possible to obtain enantiomeric purities in excess of 90%, and for the glycidyl m-nitrobenzenesulfonate up to about 99% e.e.
The compounds are produced by the following reaction schemes:
A. GLYCIDYL m-NITROBENZENESULFONATE
Figure imgf000006_0003
The (2S)-glycidyl m-nitrobenzenesulfonate preferably is purified to at least about 94% e.e., preferably at least about 96% e.e., and even more preferably at least about 98% e.e. Yields up to 98.8% e.e have been obtained in accord with this invention.
B. GLYGIDYL p-GHLOROBENZENESULFONATE
Figure imgf000006_0002
The purity of the (2S)-glycidyl p-chlorobenzenesulfonate is preferably at least about 94% e.e. and more preferably at least about 95% e.e.
C GLYCIDYL 4-CHLORO-3-NITROBENZENESULFONATE
Figure imgf000006_0001
This compound is preferably purified to at least about 90% e.e. and even more preferably to at least about 94% e.e.
(2R)-glycidyl m-nitrobenzenesulfonate, (2R)-glycidyl β-chlorobenzenesulfonate and (2R)-glycidyl 4-chloro-3- nitrobenzenesulfonate can be similarly produced by using (+) -DIPT instead of (-)-DIPT. (2R) compounds can be purified to the same enantiomeric purity as (2S) compounds.
Purification is obtained by using crystallization techniques which are well known in the art.
The crystallized compound is stable and can easily be stored at room temperature until its use is desired. The stability of these compounds means that they can be used commercially as "starting materials" in the synthesis of, for example, β-blockers. For example, a convenient, one-pot procedure can be employed to convert the glycidyl m-nitrobenzenesulfonate into an important intermediate to the β-blocker, propranolol, which can be converted to propranolol by the addition of iPrNH2 and H2O in the reaction mixture.
Figure imgf000007_0001
This substitution reaction takes place with extremely high regioselectivity, approaching 100:0 (C1:C3). The same reaction scheme can be used for converting the other compounds. Other intermediates to β-blockers, or related compounds can be readily made according to the following reaction scheme:
Figure imgf000008_0001
where X is m-nitro, p-chloro or 4-chloro-3- nltrobenzenesulfonate substituent, and ArOH is an aromatic alcohol. Any aromatic alcohol capable of displacing the sulfonate moiety can be used in the reaction to create the desired intermediate. Preferable aromatic alcohols are those that yield desired β-blockers upon subsequent reaction with a predetermined amine. The appropriate amine to use can be readily determined by the person of ordinary skill in the art.
The invention will be further illustrated by the examples that follow:
General
Crushed 3 Å molecular sieves (Aldrich Chemical Co.) were activated by heating in a vacuum oven at 160ºC and 0.05 mm Hg for at least 8 hours. Diisopropyl tartrate and titanium (IV) isopropoxide (Aldrich) were distilled under vacuum and were stored under an inert atmosphere. Allyl alcohol and cumene hydroperoxide (tech., 80%, Aldrich) were dried prior to use over 3 Å molecular sieves, but otherwise used as received. Dichloromethane (EM Reagent) was not distilled, but was also dried over 3 Å molecular sieves. 1-Naphthol (Aldrich) was sublimed prior to use.
Melting points were determined on a Thomas Hoover capillary melting point apparatus and are uncorrected. IR spectra were recorded on a Perkin-Elmer 597 spectrophotometer. 1H NMR spectra were recorded on a Bruker WM-250 (250 MHz) spectrometer with tetramethylsilane as an internal standard.
Example 1
Preparation of (2S) -Glycidyl m-nitrobenzenesulfonate.
An oven-dried 500-mL three-necked flask equipped with a magnetic stirrer, low-temperature thermometer, and rubber septums, was charged with activated 3 A powdered sieves (3.5 g) and 190 ml dichloromethane under nitrogen. D-(-)-Diisopropyl tartrate (DIPT) (1.40 g, 6mmol) was added via cannula as a solution in 1.5 ml CH2CI2, washing with an additional 1 ml CH2Cl2. Allyl alcohol (6.8 ml, 5.81 g, 0.1 mol) was then added, the mixture cooled to -5º C and Ti(OiPr)4 (1.50 ml, 1.43 g, 5 mraol) added via syringe. After stirring for 30 minutes, precooled (ice bath) cumene hydroperoxide (80%, 3.5 ml, ca. 0.2 mol) was added via cannula over a period of one hour, maintaining an internal temperature of ≤ 2ºC. The reaction mixture was stirred vigorously under nitrogen at -5 to 0ºC for six hours. After cooling to -20ºC trimethyl phosphite was added very slowly via cannula, not allowing the temperature to rise above -10ºC, and carefully monitoring the reduction of hydroperoxide [TLC in 40% EtOAc/hexane; tetramethyl phenylenediamine spray Indicator (1.5 g in MeOH:H2O:HOAc 128:25:1 ml); ca. 14.1 ml (14.89 g, 0.12 moles) of P(OMe)3 were required for complete reduction. Further excess should be avoided.] The reaction is quite exothermic and addition took one hour resulting in formation of stock solution A.
One fifth of the reaction mixture (stock solution A) (43 ml) was transferred into a 100-ml round-bottomed flask using a syringe, and triethylamine (4.2 ml, 2.05 g, 30 mmol) was added at -20°C, followed by addition of m-nitrobenzenesulfonyl chloride (4.43 g., 20 mmol) as a solution in 8 ml dichloromethane. The flask was stoppered and transferred to a freezer at -20ºC.
After 10 hours the reaction mixture was allowed to warm gradually to room temperature, then filtered through a pad of Celite, washing with additional dichloromethane. The resultant yellow solution was washed with 10% tartaric acid, followed by sat. brine, dried (MgSO4) and concentrated to afford an oil, from which volatile components (e.g. cumene, 2-phenyl-2-propanol, P(OMe)3, OP(OMe)3,etc.) were removed under high vacuum at 65ºC on a rotary evaporator equipped with a dry ice condenser. The residue was filtered through a short pad of silica gel (ca. 1 g per g crude oil), elutlng with dichloromethane. Concentration gave a lemon yellow oil which was dissolved in ca. 18 ml warm Et2O and crystallized by addition of hexane to give 2.932 g (56.6% yield) of
(2S)-glycidyl m-nitrobenzenesulfonate, m.p. 54-60ºC (96% e.e.).
Attempts to measure the e.e. directly, via 1H NMR in the presence of chiral shift reagents, or by HPLC on a chiral stationary phase, proved unsuccessful. Therefore, glycidyl m-nitrobenzenesulfonate was converted to the corresponding iodohydrin, following Conforth's published procedure (J. Chem. Soc. (1959), 112). The crude iodohydrin was then directly esterified with (R)-(+)-α-methoxy-α- (trifluoromethyl) phenylacetyl chloride to give the Mosher ester, and the e.e. measurement was made by HPLC of the ester on a chiral Pirkle column, eluting with 8% iso-proponal/hexane. The e.e. was also determined by H NMR analysis of the Mosher ester in G6D6.
A part of the crystals (2.635 g) was recrystallized twice from ethanol to afford 1.745 g of pure crystals, m.p. 63-64ºC; α + 23.0 (C-2.14, CHCI3); 99% e.e.
Figure imgf000011_0001
IR (KBr) 3114, 3090, 1611, 1532, 1469, 1451, 1428, 1354, 1280, 1257, 1188, 1132, 1086, 1076, 1004, 981, 963, 919, 913, 889, 867, 842, 820, 758, 739, 674, 667, 596, 585, 549, 524, 447, 430, 405 cm-1. NMR (250 MHz, CDCI3) δ 8.79 (t, J=1.5 Hz, 1H),
8.54 (m, 1H), 8.28 (m, 1H),
7.82 (t, J=8.0, 8.0 Hz, 1H),
4.50 (dd, J=3.4, 11.4 Hz, 1H).
4.04 (dd, J=6.0, 11.4Hz, 1H),
3.23 (m, 1H), 2.86 (t, J=4.5, 4.5 Hz, 1H)
2.64 (dd, J=2.5, 4.75 Hz, 1H).
Example 2
Substitution Reaction.
In a 5-ml round-bottomed flask equipped with a rubber septum, sodium hydride (oil free, 24 mg, 1 mmol) was suspended in DMF (1 ml, stored over 3k sieves) at room temperature under a nitrogen atmosphere. 1-Naphthol (121 mg,
0.84 mmol) was added as a solution in DMF (0.5 ml) to produce a foamy green sludge. After 15-30 minutes, a solution of
(2S)-glycidyl m-nitrobenzenesulfonate (98.8% e.e., 207 mg, 1 mmol In 0.5 ml DMF) was added. A clear green-brown solution resulted.
After 30 minutes the reaction was judged to be complete by TLC (silica gel, 40% EtOAc/hexane).
The reaction mixture was diluted with water (5 ml) and extracted with ether (3 x 10 ml). The combined extracts were washed with sat. brine, dried over anhydrous sodium sulfate and concentrated in vacuo to give crude crystalline glycidyl 1-naphthyl ether (98.8% e.e.). The e.e. was determined by NMR analysis (DCI3) of the Mosher ester, which was prepared from the crude glycidyl 1-naphthyl ether according to the method described in Example 1.
Example 3
Preparation of (2S)-glycidyl p-chlorobenzenesulfonate.
One fifth of stock solution A (43 ml) from Example 1 was transferred into a 100 ml round-bottomed flask using a syringe, and triethylamine (4.2 ml, 3.05 g, 30 mmol) was added at -20°C, followed by the addition of p-chlorobenzenesulfonyl chloride (4.22 g, 20 mmol). Thereafter, the (2S)-glycidyl p-chlorobenzenesulfonate was prepared according to the procedure of Example 1.
The crystals were obtained by crystallization of the extracts from ether-hexane (37.5% yield), m.p. 60.7-62.3ºC
(94% e.e.), which was recrystallized from ethanol-hexane to afford pure crystals, m.p. 61-62.5ºC; +
Figure imgf000013_0001
22.6 (C=2.02, CHCl3); 95.2% e.e.
IR (KBr) 3100, 1572, 1478, 1452, 1399, 1360
1281, 1260, 1180, 1136, 1089, 1019,
960, 917, 868, 826, 770, 754, 709,
628, 576, 531, 489, 448 cm"1.
NMR (250 MHz, CDCI3) δ 7.87 (d, J=8.0 Hz, 2H),
7.55 (d, J=8.0 Hz, 2H) , 4.34 (dd, J=3.4, 11.4 Hz, 1H), 3.97 (dd, J=6.0, 11.4 Hz, 1H), 3.21 (m, 1H), 2.84 (t, J=4.5, 4.5 Hz, 1H), 2.62 (dd, J=2.5, 4.75 Hz, 1H). Example 4
Preparation of (2S)-glycidyl 4-ehloro-3- nitrobenzenesulfonafce
(2S) -Glycidyl 4-chloro-3-nitrobenzenesulfonate was prepared using 4-chloro-3-nitrobenzenesulfonyl chloride instead of p-toluenesulfonyl chloride, according to the method described in Example 1. Crude crystals (mp 49-54°C, 41% yield) which were obtained by the crystallization of an oil from diethyl etherpet, ether mixture, were recrystallized from ethanol-ethyl acetate mixture to give pure crystals, mp 54.7-55.2°C, 94% e.e.
The preparation of the Mosher ester and the ee measurement of the ester were made according to the method described in Example 1.
IR(KBr) 3105, 3015, 1605, 1573, 1541, 1454, 1400, 1385, 1363,
1339, 1252, 1197, 1190, 1170, 1159, 1107, 1056, 995, 979, 963,
945, 922, 914, 899, 868, 842. 779, 767. 759, 670, 647, 591, 576,
533, 494, 452, cm-1.
NMR (250 MHz, CDU3) δ 8.43 (d, J=2Hz, 1H), 8.05 (dd,
J=2.1, 8.5 Hz, 1H), 7.79 (d, J=8.5, 1H) 4.51 (dd, J=2.8, 11.6
Hz, 1H) 4.04 (dd, J=6.5, 11.6 Hz, 1H) 3.23 (m, 1H), 2.87 (t,
J=4.5, 4.5 Hz, 1H) 2.6 (dd, J=2.5, 4.4Hz, 1H) .
This invention has been described in detail including the preferred embodiments thereof. However, it will be appreciated that those skilled in the art, upon consideration of this disclosure, may make modifications and improvements thereon without departing from the spirit and scope of the invention as set forth in the claims.

Claims

We claim:
1. A compound of the formula
Figure imgf000016_0001
2. The compound of claim 1 purified to have an enantiomeric purity of at least about 96% e.e.
3. The compound of claim 2 purified to at least about 98.8% e.e.
4. The compound of claim 2 produced from an allyllc alcohol.
5. A compound of the formula
Figure imgf000016_0002
6. The compound of claim 5 purified to have an enantiomeric purity of at least about 96% e.e.
7. The compound of claim 6 purified to at least about 98.8% e.e.
8. The compound of claim 6 produced from an allylic alcohol.
9. A compound of the formula
Figure imgf000017_0003
10. The compound of claim 7 purified to at least about 95.0% e.e.
11. The compound of claim 10 produced from an allylic alcohol.
12. A compound of the formula
Figure imgf000017_0001
13. The compound of claim 12 purified to at least about 95.0% e.e.
14. The compound of claim 12 produced from an allylic alcohol.
15. A compound of the formula
Figure imgf000017_0002
16. The compound of claim 15 purified to at least about 90% e.e.
17. The compound of claim 16 purified to at least about 94% e.e.
18. The compund of claim 16 produced from an allylic alcohol.
19. A compound of the formula
Figure imgf000018_0002
20. The compound of claim 19 purified to at least about 90% e.e.
21. The compound of claim 20 purified to at least 94% e.e.
22. The compound of claim 19 produced from an allylic alcohol.
23. A compound of the formula
Figure imgf000018_0001
produced from a mixture containing its enantiomer wherein the compound has been recrystallized to an optical purity of at least about 96.0% e.e.
24. The compound of claim 15 recrystallized to an optical purity of at least about 98.8% e.e.
25. A compound of the formula
Figure imgf000019_0001
produced from a mixture containing its enantiomer wherein the compound has been recrystallized to an optical purity of at least about 95.0% e.e.
26. A compound of the formula
Figure imgf000019_0002
produced from a mixture containing its enantiomer wherein the compound has been recrystallized to an optical purity of at least about 96.0% e.e.
27. The compound of claim 15 recrystallized to an optical purity of at least about 98.8% e.e.
28. The compound of the formula
Figure imgf000020_0001
produced from a mixture containing its enantiomer wherein the compound has been recrystallized to an optical purity of at least about 95.0% e.e.
29. A compound of the formula
Figure imgf000020_0002
produced from a mixture containing its enantiomer wherein the compound has been recrystallized to an optical purity of at least about 90% e.e.
30. The compound of claim 27 purified to an optical purity of at least about 94% e.e.
31. A compound of the formula
Figure imgf000020_0003
produced from a mixture containing its enantiomer wherein the compound has been recrystallized to an optical purity of at least about 90% e.e.
32. The compound of claim 29 purified to an optical purity of at least about 94% e.e.
33. A method for making a β- locker, said method comprising reacting glycidyl m-nitrobenzenesulfonate, glycidyl p-chlorobenzenesulfonate or glycidyl 4-chloro-3-nitrobenzenesulfonate with a suitable aromatic alcohol, ArOH, to displace the nitrobenzenesulfonate, the chlorobenzenesulfonate moiety or the 4-chloro-3- nitrobenzenesulfonate moiety and replace it with ArO-moiety, where Ar is any aromatic group and thereafter reacting the thus formed intermediate, with a predetermined amine.
34. The method of claim 7 wherein the aromatic alcohol, ArOH, is 1-naphthol.
PCT/US1987/001523 1986-06-25 1987-06-24 Optically active derivatives of glycidol WO1988000190A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US87817686A 1986-06-25 1986-06-25
US878,176 1986-06-25
US913,936 1986-10-01
US07/913,936 US4946974A (en) 1986-10-01 1986-10-01 Optically active derivatives of glycidol

Publications (1)

Publication Number Publication Date
WO1988000190A1 true WO1988000190A1 (en) 1988-01-14

Family

ID=27128478

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1987/001523 WO1988000190A1 (en) 1986-06-25 1987-06-24 Optically active derivatives of glycidol

Country Status (2)

Country Link
CA (1) CA1340738C (en)
WO (1) WO1988000190A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010642A1 (en) * 1990-01-22 1991-07-25 Nobel Chemicals Ab Process for preparing homochiral amines and process for preparing intermediates for the preparation thereof, and the intermediates prepared in accordance with this process
EP0441471A1 (en) * 1990-01-26 1991-08-14 Zeneca Limited Optical resolution
WO1993004054A1 (en) * 1991-08-22 1993-03-04 Syracuse University Method and apparatus for synthesis of highly isomerically pure stereoisomers of glycidol derivatives
US8703948B2 (en) 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
US8741916B2 (en) 2007-04-09 2014-06-03 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor
US8778956B2 (en) 2002-09-09 2014-07-15 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2755290A (en) * 1953-10-26 1956-07-17 Shell Dev Esters of sulfonic acids and certain epoxy-substituted alcohols and method for theirpreparation
US3998790A (en) * 1970-02-18 1976-12-21 Aktiebolaget Hassle Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
US4145442A (en) * 1972-04-04 1979-03-20 Aktiebolaget Hassle Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines
EP0071251A1 (en) * 1981-07-29 1983-02-09 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Novel aminoglycosides and use thereof
US4471130A (en) * 1980-08-06 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for asymmetric epoxidation
EP0157623A2 (en) * 1984-03-31 1985-10-09 Kowa Company, Ltd. Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2755290A (en) * 1953-10-26 1956-07-17 Shell Dev Esters of sulfonic acids and certain epoxy-substituted alcohols and method for theirpreparation
US3998790A (en) * 1970-02-18 1976-12-21 Aktiebolaget Hassle Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
US4145442A (en) * 1972-04-04 1979-03-20 Aktiebolaget Hassle Phenoxy-hydroxypropylamines, their preparation, and method and pharmaceutical preparations for treating cardiovascular diseases
US4210653A (en) * 1978-06-27 1980-07-01 Merck & Co., Inc. Pyridyloxypropanolamines
US4471130A (en) * 1980-08-06 1984-09-11 The Board Of Trustees Of The Leland Stanford Junior University Method for asymmetric epoxidation
EP0071251A1 (en) * 1981-07-29 1983-02-09 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Novel aminoglycosides and use thereof
EP0157623A2 (en) * 1984-03-31 1985-10-09 Kowa Company, Ltd. Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bulletin of the Chemical Society of Japan, Volume 39, published March 1966, N. NAKABAYASHI et al., "Some Reactions of the Glycidyl Esters of Sulfonic Acids", see pages 413-417. *
CHEMICAL ABSTRACTS, Volume 61, No. 6, issued 14 September 1964 (Columbus, Ohio, USA), ICHIKAWA, "Reactions of Aliphatic Amines with Epoxypropane Derivatives and their Products. I. Reactions of Aliphatic Amines with Epoxypropane Derivatives", see page 7008, column 2, the Abstract No. 7008d. *
Journal of Organic Chemistry, Volume 50, published 1985, ALDRICH, "Chiral Building Blocks", see entire document. *
Journal of the American Chemical Society, Volume 101, published 20 June 1979, D.E. McCLURE et al., "Mode of Nucleophilic Addition to Epichlorohydrin and Related Species: Chiral Aryloxy-methyloxiranes", see pages 3666-3668. *
Memoirs of the Faculty of Science, Volume 14, published 1983, M. MISHIMA et al., "Leaving Group Effects on the Acetolysis of Neophyl Arenesulfonates", see pages 199-210. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991010642A1 (en) * 1990-01-22 1991-07-25 Nobel Chemicals Ab Process for preparing homochiral amines and process for preparing intermediates for the preparation thereof, and the intermediates prepared in accordance with this process
EP0441471A1 (en) * 1990-01-26 1991-08-14 Zeneca Limited Optical resolution
WO1993004054A1 (en) * 1991-08-22 1993-03-04 Syracuse University Method and apparatus for synthesis of highly isomerically pure stereoisomers of glycidol derivatives
US8778956B2 (en) 2002-09-09 2014-07-15 Janssen Pharmaceutica Nv Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
US8703948B2 (en) 2006-11-28 2014-04-22 Janssen Pharmaceutica Nv Salts of 3-(3-amino-2-(R)-hydroxy-propyl)-1-(4-fluoro-phenyl)-8-(8-methyl-naphthalen-1-ylmethyl)-1,3,8-triaza-spiro[4.5]decan-4-one
US8741916B2 (en) 2007-04-09 2014-06-03 Janssen Pharmaceutica Nv 1,3,8-trisubstituted-1,3,8-triaza-spiro[4.5]decan-4-one derivatives as ligands of the ORL-1 receptor

Also Published As

Publication number Publication date
CA1340738C (en) 1999-09-14

Similar Documents

Publication Publication Date Title
KR100284216B1 (en) Asymmetric Preparation of Florfenicol, Thiamphenicol, Chloramphenicol and Oxazoline Intermediates
Klunder et al. Asymmetric epoxidation of allyl alcohol: efficient routes to homochiral. beta.-adrenergic blocking agents
US20080293965A1 (en) Process for the Dynamic Resolution of (Substituted) (R)- or (S)- Mandelic Acid
Boyd et al. Synthesis and absolute stereochemistry assignment of enantiopure dihydrofuro-and dihydropyrano-quinoline alkaloids
EP0452143B1 (en) Process for preparing optically active 3-hydroxypyrrolidine derivatives
CA1340738C (en) Optically active derivatives of glycidol
JP2876712B2 (en) Optically active pyranobenzoxadiazole derivative
US5153338A (en) Optically active derivatives of glycidol
US4946974A (en) Optically active derivatives of glycidol
EP0884313B1 (en) Process for producing glycidyl sulfonate derivatives
KR101379383B1 (en) A process for preparing high purity of ⒮―Metoprolol
US5344947A (en) Optically active derivatives of glycidol
US5084569A (en) Trioxy bicyclic compounds useful for preparing optically active carboxylic acids
GB2036744A (en) Eburnane derivatives
EP0089037B1 (en) Process for preparing optically active (s)-2-acetyl-7-(2-hydroxy-3-isopropylaminopropoxy)benzofuran and salts thereof
US5359097A (en) Process for preparation of glycidyl ether
JP2578797B2 (en) Method for producing N- (sulfonylmethyl) formamides
JP2832479B2 (en) Stereochemical inversion method of optically active styrene oxide and preparation of optically active glycol derivative
US6838527B2 (en) Polymer-immobilized α-iminoester
JP2973546B2 (en) Optically active 4-benzoyloxymethyl-2-oxazolidinone and method for producing the same
KR100209298B1 (en) New amine ring compounds
US5438148A (en) Process for the synthesis [R-(R*-,R*-)]-5-(3-chlorophenyl-3-[2-(3,4-dihydroxyphenyl)-1-methylethyl]-2
KR900007314B1 (en) Process for preparing n-(methoxyacetyl)-n-(2,l-dimethyl phenyl)-o-amino-oxazolidine-2-one
SU331541A1 (en) SHKM LIBRARY
US5194637A (en) Method and apparatus for synthesis of highly isomerically pure stereoisomers of glycidol derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载